Methyl 3, 4-dihydroxyphenylacetate prevents enterovirus 71 proliferation in rhabdomyosarcoma cells.
- Author:
Ying-Qiu ZHANG
1
;
Chun-Hui ZHAO
;
Zhuo YANG
Author Information
1. School of Life Science, Liaoning Normal University, Dalian 116029, China.
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
administration & dosage;
metabolism;
pharmacology;
Cell Line, Tumor;
Cell Survival;
drug effects;
Dose-Response Relationship, Drug;
Enterovirus A, Human;
physiology;
Humans;
Phenylacetates;
administration & dosage;
metabolism;
pharmacology;
RNA, Messenger;
metabolism;
Rhabdomyosarcoma;
metabolism;
pathology;
virology;
Virus Replication;
drug effects
- From:
Acta Pharmaceutica Sinica
2012;47(9):1257-1260
- CountryChina
- Language:Chinese
-
Abstract:
This article presented the inhibitory activity of methyl 3, 4-dihydroxyphenylacetate on the enterovirus 71 (EV71) infection. The EV71 VP1 capsid protein expression levels were analyzed with Western blotting. Results revealed that the compound is able to inhibit EV71 replication in rhabdomyosarcoma (RD) cells. After being incubated with the compound at a concentration of 0.01 microg x microL(-1) for 48 h, the level of EV71 vp1 mRNA in RD cells decreased by (76.83 +/- 2.47)%. The cytotoxic activity of the compound was evaluated against RD cells by a MTT assay. The results showed that the compound had low toxicity with a CC50 of 0.072 6 microg x microL(-1). These findings suggest that methyl 3, 4-dihydroxyphenylacetate is a novel compound for antiviral therapies against EV71, which merited further investigation.
